Bexarotene oral

Drug Profile

Bexarotene oral

Alternative Names: argrexin™; LGD 1069; LGD 1069 oral; Targretin capsules; Targretin oral; Targretyn oral; Targretyn™; Targrexin oral

Latest Information Update: 26 Jun 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Eisai Co Ltd; Minophagen
  • Class Antineoplastics; Benzoic acids; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists; Protein synthesis inhibitors; Retinoid X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Discontinued Non-small cell lung cancer; Thyroid cancer

Most Recent Events

  • 22 Jun 2017 Bexarotene licensed to Ewopharma for commercialisation in Hungary and Poland
  • 29 Apr 2016 Biomarkers information updated
  • 09 Jul 2015 First generic launched in USA for Cutaneous T-cell lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top